-
Mashup Score: 13The OncoAlert5k at SABCS24 - 6 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine NewsTweet
-
Mashup Score: 13The OncoAlert5k at SABCS24 - 8 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…
-
-
Mashup Score: 13The OncoAlert5k at SABCS24 - 9 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…
-
-
Mashup Score: 13The OncoAlert5k at SABCS24 - 13 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…
-
-
Mashup Score: 13The OncoAlert5k at SABCS24 - 15 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…
-
-
Mashup Score: 11
Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. In this prospective, randomized, noninferiority trial, we i…
Source: www.nejm.orgCategories: General Medicine News, General Journals & SocietTweet-
Presented at #SABCS24: The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: https://t.co/u1exDbl8XK https://t.co/FeBW6ag2gd
-
-
Mashup Score: 12024 SABCS® Takeaways - SABCS Meeting News - 3 month(s) ago
NOW AVAILABLE 2024 SABCS® Takeaways magazine Published 01-23-2025
Source: www.sabcsmeetingnews.orgCategories: General Medicine News, Oncologists1Tweet-
Read #SABCS24 Takeaways magazine for the latest updates in breast cancer research. Available now in SABCS Meeting News: https://t.co/1etSMXc0c2 https://t.co/Vui7EuPMlp
-
-
Mashup Score: 1Addition of anthracyclines to chemotherapy improves survival in high-risk breast cancer - 3 month(s) ago
SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio Breast Cancer Symposium.A higher recurrence score strongly correlated with longer survival after the addition of anthracyclines, with patients who had tumors at least 2 cm in size deriving the
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer. A higher recurrence score strongly correlated with longer survival after the addition of anthracyclines. #SABCS24 https://t.co/VfBqsSCfEr
-
-
Mashup Score: 4Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer - 3 month(s) ago
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer @SABCSSanAntonio @CWRUSOM #SABCS24 https://t.co/sgABjzdSps
-
-
Mashup Score: 4Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer - 3 month(s) ago
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer @SABCSSanAntonio @CWRUSOM #SABCS24 https://t.co/sgABjzdSps
-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…